Cevimeline

Information about Cevimeline

Cevimeline is an orally available cholinergic agonist that is used to treat symptoms of dry mouth in patients with keratoconjunctivitis sicca (Sjögren syndrome).

Liver safety of Cevimeline

Cevimeline has not been linked to serum enzyme elevations during therapy or to instances of clinically apparent liver injury.

Mechanism of action of Cevimeline

Cevimeline (se vim' e leen) is a quinuclidine derivative of acetylcholine which acts as a cholinergic muscarinic agonist. Engagement of the muscarinic cholinergic receptors causes increased secretion from exocrine glands, including sweat, salivary, lacrimal, gastric, pancreatic and intestinal glands, as well as increase smooth muscle tone and motility in the eye, respiratory tract and gastrointestinal tract. Use of daily doses of cevimeline has been shown to improve symptoms of dry mouth and increase salivary flow in patients with Sjögren syndrome and with xerostomia due to local irradiation therapy.

FDA approval information for Cevimeline

Cevimeline was approved for use in the United States in 2000 and is available in capsules of 30 mg generically and under the brand name Evoxac.

Dosage and administration for Cevimeline

The typical dose is 30 mg three times daily.

Side effects of Cevimeline

Side effects are usually mild and largely attributable to cholinergic stimulation including increased sweating, rhinitis, nausea, diarrhea, headaches, dizziness, visual disturbances and fatigue.

Sjögren Syndrome Agents

• Cholinergic Agents
  • Cevimeline
  • Pilocarpine

• Dailymed label info on Cevimeline
• FDA Cevimeline

Cevimeline Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski